Chris Ryan


Adjuvant Neratinib Does Not Improve Overall Survival in Glioblastoma, Yet May Offer Benefit for EGFR+ Subset

March 10, 2022

Although adjuvant neratinib was not found to improve progression-free or overall survival across a population of patients with glioblastoma, the agent yielded promising progression-free survival rates in a subset of patients with EGFR-positive disease.

Secondary Cytoreductive Surgery Only Offers Benefit to Select Patients With Ovarian Cancer

February 02, 2022

An expert with Stanford Health comments on the potential value of secondary cytoreductive surgery for patients with recurrent ovarian cancer and the need for careful patient selection when considering this treatment strategy.

Frontline Pembrolizumab Plus Chemo Does Not Show Superior OS Over Chemo Alone in PD-L1+ Gastric/GEJ Adenocarcinoma

January 21, 2022

Pembrolizumab plus chemotherapy did not induce clinically meaningful survival benefit, compared with chemotherapy alone, in patients with advanced gastric or gastroesophageal junction adenocarcinoma and a PD-L1 combined positive score of 1 or higher.